Catalyst-rich 2024 with data readouts planned throughout the year Company to host conference call and webcast today at 4:30 p.m. ET ATLANTA, GA, February 29, 2024 – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced its financial results and key operational accomplishments for the year ended December 31, 2023. "2023 marked another year of advancement of our ongoing clinical programs for GEO-CM04S1, our ne ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. 001-39563 GEOVAX LABS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 1900 Lake Park Drive, Suite 380 ...

ATLANTA, GA, Feb. 19, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, announced today that its Chairman and CEO, David Dodd, will present at the 2024 BIO CEO & Investor Conference, taking place in-person in New York, NY on February 26-27, 2024. Presentation Details:Presenter:        David Dodd, Chairman & CEODate/Time:       February 26, 2024, 4:15 pm ETLocation:          New ...

Intellectual Property Assets Strengthened for Cancer Immunotherapy Programand for Marburg Virus and HIV Vaccines ATLANTA, GA, Feb. 13, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced multiple actions by global patent offices strengthening the Company's intellectual property assets. The Japanese Patent Office issued a Decision of Grant notifying GeoVax of the a ...

ATLANTA, GA, Jan. 29, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc.  (NASDAQ:GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that the Company's Board of Directors has approved a reverse stock split of its issued and outstanding shares of common stock, par value $0.001 per share (the "Common Stock"), at a ratio of 1-for-15. The Company is effecting the reverse split to regain compliance with the $1.00 minimum bid ...

Therapy Demonstrated Safety, Stabilization/Shrinkage of Treated Tumors Expanded Development for Monotherapy and Combination Therapy Anticipated ATLANTA, GA, Jan. 04, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced the closure of patient enrollment for the Phase 1/2 clinical study evaluating Gedeptin® in patients suffering from advanced head and neck cancer. Ke ...

Patent Covers Multiple Component Vaccine for Both Prevention and Treatment ATLANTA, GA, Jan. 03, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that the U.S. Patent and Trademark Office has issued Patent No. 11,857,611 to GeoVax, pursuant to the Company's patent application No. 17/726,254 titled "Compositions and Methods for Generating an Immune Response to T ...

ATLANTA, GA, Dec. 27, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire - GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that David Dodd, Chief Executive Officer, will present at the Biotech Showcase coinciding with the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, January 8-11, 2024. Presentation Details:Presenter:        David Dodd, Chairman & CEODate/Time:       January 8, 2023, 2:30 pm PS ...

ATLANTA, GA, Dec. 27, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire - GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that David Dodd, Chief Executive Officer, will present at the Biotech Showcase coinciding with the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, January 8-11, 2024. Presentation Details:Presenter:        David Dodd, Chairman & CEODate/Time:       January 8, 2023, 2:30 pm P ...

GeoVax Labs, Inc. (NASDAQ:GOVX) Q3 2023 Earnings Conference Call November 8, 2023 4:30 PM ET Company Participants Max Gadicke - Stern, IR David Dodd - Chairman and CEO Mark Reynolds - CFO Kelly McKee - Chief Medical Officer Conference Call Participants Jason Kolbert - Dawson James Operator Good afternoon, and welcome everyone to the GeoVax Third Quarter 2023 Corporate Update Call. My name is Mandeep and I will facilitate today's call. With me are David Dodd, Chairman and CEO; Mark Reynolds, Chief Financial ...